#### CLOTRIMAZOLE- clotrimazole lozenge Hikma Pharmacuticals USA USA Inc.

-----


Clotrimazole Troche(lozenges) USP FOR TOPICAL ORAL ADMINISTRATION

**Rx only** 

#### DESCRIPTION

Each Clotrimazole Troche (lozenge) USP contains 10 mg clotrimazole USP [1-(o-chloro- $\alpha, \alpha$ -diphenylbenzyl) imidazole], a synthetic antifungal agent, for topical use in the mouth.

Structural Formula:



# $C_{22}H_{17}CIN_2$

The troche dosage form is a large, slowly dissolving tablet (lozenge) containing 10 mg of clotrimazole USP dispersed in croscarmellose sodium, dextrates, magnesium stearate, microcrystalline cellulose and povidone.

# CLINICAL PHARMACOLOGY

Clotrimazole is a broad-spectrum antifungal agent that inhibits the growth of pathogenic yeasts by altering the permeability of cell membranes. The action of clotrimazole is fungistatic at concentrations of drug up to 20 mcg/mL and may be fungicidal *in vitro* against *Candida albicans* and other species of the genus *Candida* at higher concentrations. No single-step or multiple-step resistance to clotrimazole has developed during successive passages of *Candida albicans* in the laboratory; however, individual organism tolerance has been observed during successive passages in the laboratory. Such *in vitro* tolerance has resolved once the organism has been removed from the antifungal environment.

After oral administration of a 10 mg clotrimazole troche to healthy volunteers, concentrations sufficient to inhibit most species of *Candida* persist in saliva for up to three hours following the approximately 30 minutes needed for a troche to dissolve. The long term persistence of drug in saliva appears to be related to the slow release of

clotrimazole from the oral mucosa to which the drug is apparently bound. Repetitive dosing at three hour intervals maintains salivary levels above the minimum inhibitory concentrations of most strains of *Candida*; however, the relationship between *in vitro* susceptibility of pathogenic fungi to clotrimazole and prophylaxis or cure of infections in humans has not been established.

In another study, the mean serum concentrations were 4.98  $\pm$  3.7 and 3.23  $\pm$  1.4 nanograms/mL of clotrimazole at 30 and 60 minutes, respectively, after administration as a troche.

# INDICATIONS AND USAGE

Clotrimazole is indicated for the local treatment of oropharyngeal candidiasis. The diagnosis should be confirmed by a KOH smear and/or culture prior to treatment.

Clotrimazole is also indicated prophylactically to reduce the incidence of oropharyngeal candidiasis in patients immunocompromised by conditions that include chemotherapy, radiotherapy, or steroid therapy utilized in the treatment of leukemia, solid tumors, or renal transplantation. There are no data from adequate and well-controlled trials to establish the safety and efficacy of this product for prophylactic use in patients immunocompromised by etiologies other than those listed in the previous sentence. (See DOSAGE AND ADMINISTRATION.)

# CONTRAINDICATIONS

Clotrimazole is contraindicated in patients who are hypersensitive to any of its components.

#### WARNING

Clotrimazole is not indicated for the treatment of systemic mycoses including systemic candidiasis.

# PRECAUTIONS

Abnormal liver function tests have been reported in patients treated with clotrimazole troches; elevated SGOT levels were reported in about 15% of patients in the clinical trials. In most cases the elevations were minimal and it was often impossible to distinguish effects of clotrimazole from those of other therapy and the underlying disease (malignancy in most cases). Periodic assessment of hepatic function is advisable particularly in patients with pre-existing hepatic impairment.

Since patients must be instructed to allow each troche to dissolve slowly in the mouth in order to achieve maximum effect of the medication, they must be of such an age and physical and/or mental condition to comprehend such instructions.

#### Carcinogenesis

An 18 month dosing study with clotrimazole in rats has not revealed any carcinogenic effect.

#### **Use In Pregnancy**

*Pregnancy Category C:* Clotrimazole has been shown to be embryotoxic in rats and mice when given in doses 100 times the adult human dose (in mg/kg), possibly secondary to maternal toxicity. The drug was not teratogenic in mice, rabbits, and rats when given in doses up to 200, 180, and 100 times the human dose.

Clotrimazole given orally to mice from nine weeks before mating through weaning at a dose 120 times the human dose was associated with impairment of mating, decreased number of viable young, and decreased survival to weaning. No effects were observed at 60 times the human dose. When the drug was given to rats during a similar time period at 50 times the human dose, there was a slight decrease in the number of pups per litter and decreased pup viability.

There are no adequate and well controlled studies in pregnant women. Clotrimazole troches should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

#### **Pediatric Use**

Safety and effectiveness of clotrimazole in children below the age of 3 years have not been established; therefore, its use in such patients is not recommended.

The safety and efficacy of the prophylactic use of clotrimazole troches in children have not been established.

#### Geriatric Use

Clinical studies of clotrimazole did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.

# **ADVERSE REACTIONS**

Abnormal liver function tests have been reported in patients treated with clotrimazole troches; elevated SGOT levels were reported in about 15% of patients in the clinical trials (See PRECAUTIONS).

Nausea, vomiting, unpleasant mouth sensations and pruritus have also been reported with the use of the troche.

# OVERDOSAGE

No data available.

# DRUG ABUSE AND DEPENDENCE

No data available.

#### **DOSAGE AND ADMINISTRATION**

Clotrimazole is administered only as a lozenge that must be slowly dissolved in the mouth. The recommended dose is one troche five times a day for fourteen consecutive days. Only limited data are available on the safety and effectiveness of the clotrimazole troche after prolonged administration; therefore, therapy should be limited to short term use, if possible.

For prophylaxis to reduce the incidence of oropharyngeal candidiasis in patients immunocompromised by conditions that include chemotherapy, radiotherapy, or steroid therapy utilized in the treatment of leukemia, solid tumors, or renal transplantation, the recommended dose is one troche three times daily for the duration of chemotherapy or until steroids are reduced to maintenance levels.

# HOW SUPPLIED

#### Clotrimazole Troche (lozenges) USP

# 10 mg troche is supplied as white, round, flat face beveled edge troche with product identification "54 552" on one side and plain on the other side.

NDC 0054-4146-22: Bottle of 70 Troches

NDC 0054-4146-23: Bottle of 140 Troches

NDC 0054-8146-22: 7x10 Unit-Dose Troches

Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]

#### Avoid freezing.

Distributed by: **Hikma** 

#### Pharmaceuticals USA Inc.

Berkeley Heights, NJ 07922

#### C50000435/01

**Revised July 2021** 

PACKAGE/LABEL PRINCIPAL DISPLAY PANEL



#### PACKAGE/LABEL PRINCIPAL DISPLAY PANEL



	trimazole lozo	enge											
Pı	oduct Info	rmation											
Dr	oduct Type		ним	AN PRESC	RIPTION DRUG	Item Cor	de (Source)		054-4146				
	ute of Admir	victration		AL. TOPICAL			de (Source)	nDe.e					
RC	ute of Admir	listration	014	AL, TOPICAL	-								
Ac	tive Ingred	lient/Acti	ive Moi	ietv									
	3			ent Name	2		Basis of St	trenath	Strengt				
CL	OTRIMAZOLE (	UNII: G07GZ	297H65) (	CLOTRIMAZ	ZOLE - UNII:G07GZ	97H65)	CLOTRIMAZ OL	E	10 mg				
In	active Ingr	edients											
				gredien				St	rength				
	OSCARMELLO			280L1HH48	3)								
	XTRATES (UNII:												
					MAGNESIUM STEARATE (UNII: 70097M6I30)								
MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)													
	VIDONE, UNSP	PECIFIED (U			D61U)								
	VIDONE, UNSF	PECIFIED (U			D61U)								
PO	vidone, unsf oduct Char		NII: FZ98		D61U)								
PO Pr Co	oduct Char		INII: FZ98		D61U) Score		n	o score					
PO Pr Co Sh	oduct Char lor ape		NII: FZ98		Score Size		1	6mm					
PO Pr Co Sh Fla	oduct Char lor ape ivor		INII: FZ98		Score		1						
PO Pr Co Sh Fla	oduct Char lor ape		INII: FZ98		Score Size		1	6mm					
PO Pr Co Sh Fla Co	oduct Char lor ape ivor		INII: FZ98		Score Size		1	6mm					
PO Pr Co Sh Fla Co	oduct Char lor ape ivor ntains		i <b>CS</b> WHITE ROUND		Score Size Imprint Code	Mark	1	6mm 4;552 <b>Marke</b>	ting End				
PO Pr Co Sh Fla Co Pa #	oduct Char lor ape ivor ntains ckaging		NII: FZ 98	9GH94E) I <b>ge Desc</b> STIC; Type	Score Size Imprint Code	Mark 07/29/24	1 5 eting Start Date	6mm 4;552 <b>Marke</b>	_				
PO Pr Co Sh Fla Co Pa #	oduct Char lor ape ivor ntains ickaging Item Code	70 in 1 BO	NII: FZ 98 iCS WHITE ROUND Packa TTLE, PLA on Produc DTTLE, PL	9GH94E) <b>ige Desc</b> STIC; Type t ASTIC; Typ	Score Size Imprint Code		eting Start Date 004	6mm 4;552 <b>Marke</b>	_				
PO Pr Co Sh Fla Co Pa #	oduct Char lor ape ovor ntains ackaging item Code NDC:0054- 4146-22 NDC:0054-	70 in 1 BO Combinatio 140 in 1 BC	NII: FZ 98 iCS WHITE ROUND Packa TTLE, PLA on Produc DTTLE, PL	9GH94E) <b>ige Desc</b> STIC; Type t ASTIC; Typ	Score Size Imprint Code	07/29/2	eting Start Date 004	6mm 4;552 <b>Marke</b>	-				
PO Pr Co Sh Fla Co Pa #	oduct Char lor ape ovor ntains ackaging ltem Code NDC:0054- 4146-22 NDC:0054-	70 in 1 BO Combinatio 140 in 1 BC Combinatio	Packa	9GH94E) <b>ige Desc</b> STIC; Type t ASTIC; Typ t	Score Size Imprint Code	07/29/2	eting Start Date 004	6mm 4;552 <b>Marke</b>	_				
PO Pr Co Sh Fla Co Pa # 1	oduct Char lor ape ivor ntains ckaging item Code NDC:0054- 4146-22 NDC:0054- 4146-23	70 in 1 BO Combinatio 140 in 1 BC Combinatio	Packa TTLE, PLA on Produc	9GH94E) <b>ige Desc</b> STIC; Type t ASTIC; Typ t	Score Size Imprint Code Imprint Code Code Code Code Code Code Code Code	07/29/2 07/29/2 Marke	eting Start Date 004	6mm 4;552 Marke	_				

# CLOTRIMAZOLE

clotrimazole lozenge

<b>Product Infor</b>	mation							
Product Type				ltom Cor	le (Source)		054-8146	
						NDC.C	004-0140	
Route of Admin	Route of Administration ORAL, TOPICAL							
Active Ingred	ient/Acti	ve Moiety						
	Ingredient Name Basis of St						Strengt	
CLOTRIMAZOLE (L	JNII: G07GZ	97H65) (CLOTRIM	97H65) (CLOTRIMAZOLE - UNII:G07GZ97H6			LE	10 mg	
Inactive Ingre	diants							
Inactive Ingredients Ingredient Name						St	Strength	
CROSCARMELLOSE SODIUM (UNII: M280L1HH48)								
DEXTRATES (UNII:	G263MI44R	U)						
MAGNESIUM STEA	RATE (UNII	: 70097M6I30)						
POVIDONE, UNSPI	ECIFIED (U	NII: FZ989GH94E)						
	acteristi	cs						
Color	acteristi	WHITE	Score			no score		
Color Shape	acteristi		Size		1	16mm		
<b>Product Chara</b> Color Shape Flavor	acteristi	WHITE			1			
Color Shape Flavor	acteristi	WHITE	Size		1	16mm		
Color Shape	acteristi	WHITE	Size		1	16mm		
Color Shape Flavor Contains <b>Packaging</b>	acteristi	WHITE	Size Imprint Code		1	16mm 54;552 <b>Marke</b>	ting End	
Color Shape Flavor Contains Packaging # Item Code	70 in 1 CA	WHITE ROUND Package Des	Size Imprint Code		ting Start Date	16mm 54;552 <b>Marke</b>	ate	
Color Shape Flavor Contains Packaging # Item Code 1 NDC:0054-8146-	70 in 1 CA	WHITE ROUND Package Des	Size Imprint Code	C	ting Start Date	16mm 54;552 <b>Marke</b> D	ate	
Color Shape Flavor Contains Packaging # Item Code 1 NDC:0054-8146- 22	70 in 1 CAI 1 in 1 BLIS	WHITE ROUND Package Des	Size Imprint Code	C	ting Start Date	16mm 54;552 <b>Marke</b> D	ate	
Color Shape Flavor Contains Packaging # Item Code 1 NDC:0054-8146- 22	70 in 1 CAI 1 in 1 BLIS Product	WHITE ROUND Package Des RTON TER PACK; Type 0	Size Imprint Code	C	ting Start Date	16mm 54;552 <b>Marke</b> D	ate	
Color Shape Flavor Contains Packaging # Item Code 1 NDC:0054-8146- 22	70 in 1 CAI 1 in 1 BLIS Product	WHITE ROUND Package Des RTON TER PACK; Type 0	Size Imprint Code cription : Not a Combination	07/29/200	ting Start Date	16mm 54;552 Marke D 07/31/202	p <b>ate</b>	
Color Shape Flavor Contains Packaging Item Code 1 NDC:0054-8146- 2 1 NDC:0054-8146- 2 1 Marketing Marketing	70 in 1 CAI 1 in 1 BLIS Product	WHITE ROUND Package Des RTON TER PACK; Type 0 Nation	Size Imprint Code cription : Not a Combination	07/29/200	ting Start Date 4 eting Start Date	16mm 54;552 Marke D 07/31/202	eting End Date	

Labeler - Hikma Pharmacuticals USA USA Inc. (080189610)

Establishment						
Name	Address	ID/FEI	<b>Business Operations</b>			
West-Ward Columbus Inc.		058839929	MANUFACTURE(0054-4146, 0054-8146)			